Insulet (NASDAQ:PODD) Sets New 52-Week Low – Should You Sell?

Insulet Corporation (NASDAQ:PODD)’s share price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $139.23 and last traded at $139.9680, with a volume of 159812 shares. The stock had previously closed at $145.76.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Truist Financial reduced their price target on shares of Insulet from $250.00 to $219.00 and set a “buy” rating for the company in a report on Thursday, June 11th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Insulet in a research note on Tuesday. They set a “buy” rating and a $190.00 price objective on the stock. Barclays reduced their price objective on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research note on Thursday, May 7th. The Goldman Sachs Group restated a “buy” rating and set a $205.00 target price on shares of Insulet in a report on Wednesday, May 27th. Finally, Oppenheimer reduced their price target on Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Twenty-two research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $238.67.

Insulet Stock Performance

The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The firm’s 50 day simple moving average is $161.91 and its 200 day simple moving average is $223.32. The firm has a market capitalization of $10.20 billion, a price-to-earnings ratio of 34.17, a PEG ratio of 1.09 and a beta of 1.13.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. During the same quarter last year, the business posted $1.02 EPS. The company’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. Sell-side analysts forecast that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Insider Activity

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.36% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Insulet

A number of institutional investors have recently added to or reduced their stakes in the stock. Empowered Funds LLC raised its position in shares of Insulet by 38.1% during the 1st quarter. Empowered Funds LLC now owns 2,880 shares of the medical instruments supplier’s stock worth $604,000 after purchasing an additional 795 shares during the last quarter. Avidity Partners Management LP purchased a new stake in Insulet during the 1st quarter worth approximately $2,098,000. Glenmede Trust Co. NA lifted its position in shares of Insulet by 6.5% in the first quarter. Glenmede Trust Co. NA now owns 2,717 shares of the medical instruments supplier’s stock valued at $570,000 after acquiring an additional 166 shares in the last quarter. Essential Partners LLC lifted its position in shares of Insulet by 9,980.0% in the first quarter. Essential Partners LLC now owns 504 shares of the medical instruments supplier’s stock valued at $106,000 after acquiring an additional 499 shares in the last quarter. Finally, Western Wealth Management LLC acquired a new stake in shares of Insulet in the first quarter worth approximately $80,000.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.